1-(4-nitrophenyl)-5-nitrouracil | 59987-33-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-nitrophenyl)-5-nitrouracil
• 英文别名: 5-nitro-1-(p-nitrophenyl)uracil；5-nitro-1-(4-nitro-phenyl)-1H-pyrimidine-2,4-dione；5-Nitro-1-(4-nitrophenyl)pyrimidine-2,4-dione
• CAS: 59987-33-6
• 化学式: C₁₀H₆N₄O₆
• 分子量: 278.181
• InChiKey: CYAAFLGWAUCWEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(4-nitrophenyl)-5-nitrouracil 在 氨 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以57%的产率得到1-(3-amino-2-nitroacryloyl)-3-(p-nitrophenyl)urea
  参考文献：
  名称：

  在5位上具有吸电子基团的尿嘧啶衍生物与胺的新反应：尿嘧啶N 1部分与胺之间的交换反应

  摘要：

  具有在5-位的吸电子基团例如硝基，氨基甲酰基和氰基的1，3-二取代的尿嘧啶与伯胺的反应导致尿嘧啶环的N 1部分与胺部分交换。交换反应受5-和N 1-位上取代基的性质影响。用加成，开环和闭环的方式解释反应顺序。

  DOI：

  10.1039/p19900000367
• 作为产物：
  描述：

  1-(4-nitro-phenyl)-1H-pyrimidine-2,4-dione 在 硫酸 、 硝酸 作用下， 生成 1-(4-nitrophenyl)-5-nitrouracil
  参考文献：
  名称：

  尿嘧啶衍生物N-1芳构化的简便方法

  摘要：

  1-（4-硝基苯基）-和1-（2,4-二硝基苯基）尿嘧啶衍生物是通过使用1-氟-4-硝基苯或1-氟-2,4将尿嘧啶及其5-取代衍生物直接芳基化制得的-二硝基苯在碱的存在下。还介绍了新获得的尿嘧啶衍生物在进一步合成中的应用。

  DOI：

  10.1016/j.tetlet.2006.04.130

文献信息

• THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS
  申请人：BROWN Dennis M.

  公开号：US20160045502A1

  公开（公告）日：2016-02-18

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.

  本发明描述了一种改善先前受到治疗性能不佳限制的治疗剂的治疗效果的方法和组合物，通过改善单药疗法的功效或减少副作用。这种方法和组合物特别适用于芥子碱基烷基化剂，例如尿嘧啶芥和其类似物、衍生物或前药，包括6-甲基尿嘧啶芥和6-乙基尿嘧啶芥。
• HIROTA, KOSAKU;KITADE, YUKIO;SAJIKI, HIRONAO;MAKI, YOSHIFUMI;YOGO, MOTOI, J. CHEM. SOC. PERKIN TRANS. PT 1,(1990) N, C. 367-373
  作者：HIROTA, KOSAKU、KITADE, YUKIO、SAJIKI, HIRONAO、MAKI, YOSHIFUMI、YOGO, MOTOI

  DOI：——

  日期：——
• COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS
  申请人：Orbus Therapeutics, Inc.

  公开号：US20190133985A1

  公开（公告）日：2019-05-09

  Eflornithine is an agent that can be used to treat glioma, especially glioma of WHO Grade II or Grade III such as anaplastic glioma. Eflornithine can suppress or prevent mutations in glioma which can cause the glioma to progress to a higher grade. Compositions and methods can include eflornithine or a derivative or analog of eflornithine, together with other agents such as conventional anti-neoplastic agents for treatment of glioma, inhibitors of polyamine transport, polyamine analogs, or S-adenosylmethionine decarboxylase inhibitors. Eflornithine or derivatives or analogs thereof can also be used to treat a range of non-glioma malignancies, including both malignancies of the central nervous system and other malignancies.
• [EN] THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS<br/>[FR] BÉNÉFICE THÉRAPEUTIQUE DE COMPOSÉS CHIMIQUES ADMINISTRÉS DE FAÇON SOUS-OPTIMALE
  申请人：BROWN DENNIS M

  公开号：WO2014168986A1

  公开（公告）日：2014-10-16

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.
• Novel reaction of uracil derivatives possessing electron-withdrawing groups at the 5-position with amines: exchange reaction between the N1-portion of uracils and amines
  作者：Kosaku Hirota、Yukio Kitade、Hironao Sajiki、Yoshifumi Maki、Motoi Yogo

  DOI：10.1039/p19900000367

  日期：——

  The reaction of 1,3-disubstituted uracils possessing an electron-withdrawing group such as nitro, carbamoyl, and cyano at the 5-position with primary amines resulted in the exchange of the N1-portion of the uracil ring with the amine moiety. The exchange reactions were influenced by the nature of substituents at the 5- and N1-position. The reaction sequence is explained in terms of addition, ring-opening

  具有在5-位的吸电子基团例如硝基，氨基甲酰基和氰基的1，3-二取代的尿嘧啶与伯胺的反应导致尿嘧啶环的N 1部分与胺部分交换。交换反应受5-和N 1-位上取代基的性质影响。用加成，开环和闭环的方式解释反应顺序。